WeightLossScout

WeightLossScout — Weekly-refreshed GLP-1 telehealth price tracker: per-provider monthly cost bands for compounded semaglutide and compounded tirzepatide (observed floor-to-ceiling per provider, e.g. $89-$249, $130-$249, $149-$349), each row carrying a stability status and a weekly verification date, alongside branded no-insurance reference ranges (Ozempic $936-$1,150, Wegovy $1,300-$1,500, Mounjaro $1,050-$1,200, Zepbound $550-$650 self-pay vial), plus a 12-factor provider scorecard covering pricing, clinical quality, medication access and patient experience, and free patient tools (eligibili…

WeightLossScout offers (Alternative, Price) — ~14-18 tracked provider rows x 2 medications x 2 price points (floor and ceiling) with a stability status and weekly date = roughly 56-72 priced observations per weekly snapshot. At the stated weekly cadence that compounds to ~2,900-3,700 provider-medication price observations per year — a materially higher refresh frequency than the monthly indices elsewhere in this pool. Adjacent assets add ~14+ per-provider review pages each scored on 12 factors (~170 scored cells) and the branded reference ranges for 4 drugs..

Weekly compounded-GLP-1 price monitoring at provider level — the compounded category is legally contested and reprices fastest, so weekly cadence is the scarce dimension here; promotional-discount intensity tracking via the floor-vs-ceiling price band per provider; affiliate-channel economics analysis (which providers pay, and what they pay relative to their published price position); category-displacement measurement of compounded discounting against branded self-pay ranges (the site's own framing: compounded runs 75-90% below branded); provider-quality scoring datasets from the 12-factor scorecard; and tool-generated intent data — the prior-authorization letter generator and cost calculator encode real patient coverage obstacles in the buyer's own words.

Coverage spans US; Health Care Facilities, Pharmaceuticals; alternative, price; equities.